EVP, CLO, Alkermes, Inc.

EVP R&D, Chief Medical Officer

SVP, Chief Commercial Officer

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Institution	Shares	Value	Change
BlackRock	29,235,739	$1.5B	INCREASED
Vanguard	18,464,981	$967M	INCREASED
Baker Bros. Advisors	10,012,267	$525M	UNCHANGED
State Street	9,160,575	$480M	DECREASED
T. Rowe Price	7,828,275	$410M	INCREASED

Insider	Type	Shares	Value	Date
David Joseph Gaffin (EVP, CLO, Alkermes, Inc.)	SELL	2,034	$98K	2026-09-03
Craig C. Hopkinson (EVP R&D, Chief Medical Officer)	EXERCISE	5,000	$123K	2026-09-01
Craig C. Hopkinson (EVP R&D, Chief Medical Officer)	SELL	9,000	$423K	2026-09-01
Christian Todd Nichols (SVP, Chief Commercial Officer)	SELL	664	$33K	2026-08-17
Christian Todd Nichols (SVP, Chief Commercial Officer)	SELL	6,912	$340K	2026-08-17

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	PURCHASE	$15,001 - $50,000	2026-07-30
Gilbert Cisneros (Democrat)	PURCHASE	$15,001 - $50,000	2026-07-29

Alkermes Inc. plc (ALKS) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades